RxDoctor Payments Data

Farida Hassan, MD

Internal Medicine · Jackson, NJNPI 1962677583

Payments from drug & device makers

$196in general payments, 2019–2025

Across 14 payments — averaging $14.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$29
  • Johnson & Johnson$28
  • AbbVie$27
  • Eisai Inc.$26
  • Philips North America LLC$19
  • Radius Health, Inc.$15
  • plus $53 from 4 others

What the payments were for

  • Food & beverage$196100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$196 in reported general payments places this provider in the 40th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$160,293
Medicare patients
328
Services billed
1,757

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban246$111,631
JanuviaSitagliptin Phosphate60$38,033
XareltoRivaroxaban68$30,842
FarxigaDapagliflozin Propanediol25$14,821
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$13,706
MyrbetriqMirabegron43$13,595
Breo ElliptaFluticasone/Vilanterol35$13,344
RetacritEpoetin Alfa-Epbx20$9,284
EntrestoSacubitril/Valsartan15$8,211
JardianceEmpagliflozin13$7,814
CreonLipase/Protease/Amylase35$7,382
Memantine Hcl138$6,394
TrintellixVortioxetine Hydrobromide13$6,158
Autoshield Duo Pen NeedlePen Needle,dual Safety,diabetc43$4,199
Metoprolol Succinate300$4,138

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Retacrit$14$120,915266 claims
Johnson & JohnsonXarelto$28$30,84268 claims
Astellas Pharma US IncMyrbetriq$15$13,59543 claims
AbbVieCreon, Synthroid$27$8,53847 claims
NovartisEntresto$12$8,21115 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$29$6,15813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Jackson

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →